Health and Fitness Health and Fitness
Mon, February 6, 2012
Sun, February 5, 2012
Sat, February 4, 2012
Fri, February 3, 2012

2012 Economic Outlook - Report Highlights VIVUS, Inc. and Biogen Idec Inc.


Published on 2012-02-03 06:09:10 - Market Wire
  Print publication without navigation


February 03, 2012 09:00 ET

2012 Economic Outlook - Report Highlights VIVUS, Inc. and Biogen Idec Inc.

HONG KONG--(Marketwire - Feb 3, 2012) - Today, [ www.BrightonMarkets.com ] announced new reports highlighting VIVUS, Inc. (NASDAQ: [ VVUS ]) and Biogen Idec Inc. (NASDAQ: [ BIIB ]). Gain market insight with full analysis and research downloads available at [ www.BrightonMarkets.com/index.php?coa=VVUS&cob=BIIB ].

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on VIVUS, Inc. for its current position within the healthcare industry. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. The full research report on VIVUS, Inc. (NASDAQ: [ VVUS ]) is available here: [ www.BrightonMarkets.com/index.php?coa=VVUS ].

Brighton Markets has released research on Biogen Idec Inc. for its changing role within the healthcare industry. Biogen Idec Inc. (Biogen Idec) is a global biotechnology company focused on discovering, developing, manufacturing and marketing products for the treatment of neurological disorders and other serious diseases. The Company's products include AVONEX, TYSABRI, FUMADERM and RITUXAN. The full research report on Biogen Idec Inc. (NASDAQ: [ BIIB ]) is available here: [ www.BrightonMarkets.com/index.php?cob=BIIB ].

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.


Contributing Sources